|Day Low/High||67.03 / 67.68|
|52 Wk Low/High||52.04 / 77.03|
Aetna's additive effects on CVS's earnings might be front and center, but it isn't fully actualized just yet.
As CVS Health's stock continues to run, management's careful approach should be encouraging for beleaguered investors.
CVS is setting up an anticipated new stock trajectory for investors.
I've spotlighted three blue-chip companies with stock prices that are at ridiculously low valuations right now.
The free press that the progressive push for Medicare got on Tuesday morning is hurting the healthcare sector.
The health benefit giant's fundamentals are good, but there are more symptoms to consider for a proper examination.
It has become almost too onerous to own something that could be in Amazon's crosshairs.
The consumer is alive, well, and might benefit from a thaw with China and easy to get jobs. So would Boeing and Caterpillar.
Look at the entirety of your portfolio and make sure there are no earnings blow-ups coming from the companies that you own.
As I sit down to eat some lunch and gather my thoughts for the afternoon, here are some of the items I'll be reading up on: · Outgoing FDA chief Scott Gottlieb raises 'concern' over Walgreens Boosts Alliance, Inc. , and CVS Health Corp. selling CBD...
I have had to think long and hard about Lyft, the stock, not the ride-sharing company.
In fact, the de-emphasizing of cigarettes was blamed for declining same store sales.
The contagion in pharmacy stocks is spreading and secular trends aren't helping to find a solution anytime soon.
Might this be the bottom? It might.
Walgreens weak guidance is sending shares plummeting on Tuesday.
While today's action isn't attractive, we were ripe for a little profit-taking.
While the two companies seem very similar on the surface, CVS and Walgreens are different stocks for different types of investors.
I think sometimes the best way to parse the temperament is to go over the most obviously 'wrong' moves and address why they might not be wrong at all.
With all the unknowns surrounding Boeing it's way too early to take a position in the aircraft maker; the same is not true with CVS.
National security is job one. Cutting a nice deal with China that benefits both sides must come second.
This is hope, not fact -- don't pay more for the same old thing.
The market's reaction to the pharmacy giant's acquisition of Aetna is providing a rare opportunity to buy a quality company at a value price.